Pharmaceutical Intermediate CAS 943319-70-8 Ponatinib Raw Material Ponatinib Powder Ponatinib

• CAS No.: 943319-70-8
• Shelf Life: 3 Years
• Grade: Pharmaceutical Grade
• Product Name: Ponatinib
• Transport Package: Vials
• Specification: cusmoerised
• Trademark: OEM/ODM
• Origin: Fujian China
• Production Capacity: 100kg Per Month

Product Description

 

Products Description

Product Name	Ponatinib
Appearance	Yellow Powder
CAS No.	943319-70-8
MF	C29H27F3N6O

Ponatinib is an anticancer drug. It was approved by FDA in December 2012 for the treatment of adult chronic myelogenous leukemia (CML) and "Philadelphia chromosome positive" (PH +) acute lymphoblastic leukemia (ALL). It is mainly used to treat patients who do not respond to dasatinib or nillotinib therapy, or who are unable to tolerate dasatinib or nillotinib, and who are not suitable for subsequent treatment with imatinib. It can also be used to treat patients with a genetic mutation (the "T315I mutation") that makes patients resistant to imatinib, dasatinib, or nilotinib. It is also used to treat CML and pH +ALL in adults who have not been treated with other TKIs. It is currently the only marketed drug that is effective against the BCR-ABL kinase T315I mutation. 

Function

Ponatinib was approved in the European Union in July 2013 through a centralised approval process. Panatinib is the third generation of multi-target tyrosine kinase inhibitors. Typical drugs of multi-target tyrosine kinase inhibitors include sunitinib, imatinib, sorafenib and vataranib., for he (Ponatinib) can effectively inhibit the in vitro FGFR1-4 kinase activity, its IC50 alue concentration,2,18 2 and 8 nmol/L respectively, in the absence of interleukin - 3 cells, FGFR1, on behalf of, to curb cells - 4 kinase expression of IC50 alue concentration were 8 August 24 and 34 nmol/L, and tested in each cell, for inhibition of FGFR1-4 phosphorylation, its IC50 alue concentration is 39 29 32 and 39 nmol/L respectively tested on endometrial bladder Stomach and thymus in multiple cell lines FGFR inhibition, relatively, compared with other drugs for showed obvious pharmacological effects, such as its inhibit endometrial AN3CA and MFE - 296 cell proliferation GI50 value of 14 and 61 nmol/L, it shows that, for he is a powerful FGFR inhibitors in mice tumor xenograft model, each day 10 mg/kg or 30 mg/kg, tumor inhibition rate were 49% and 82%, respectively.

 

 

Shipping Terms
By Express	By Air	By Sea
Suitable for under 50kg Fast:3-4 days High cost Door to door service Easy to pick up the goods	Suitable for more than 50kg Fast:3-4 days High cost Airport to airport Professional broker needed	Suitable for more than 500kg Slow:15-30 days Low cost Port to port Professional broker needed

 

 

Tirzepatide, is a medication used for the treatment of type 2 diabetes.  Tirzepatide is given by weekly subcutaneous injection (under the skin).

Glucagon-like peptide-1 and glucose-dependent insuli otropic polypeptide are hormones involved in blood sugar control.  After a person has eaten, these hormones are secreted by cells of the intestines and in turn cause the secretion of insuli.  Tirzepatide is a first-in-class medication.  It is a GIP-analogue that activates both the GLP-1 and GIP receptors, leading to improved blood sugar control.

Function

• Helps slow food leaving your stomach
• Helps prevent your liver from making too much sugar
• Helps the pancreas produce more insul when your blood sugar levels are high
• Can help control blood glucose
• Can reduce hyperglycemia, especially after meals
• Can reduce fasting insul and fasting glucose
• Can reduce hemoglobin A1c
• Can decrease appetite and caloric intake, while inhibiting weight gain
• Has been shown to lower triglyceride levels and oxidative stress from high LDL
• Has been shown to help induce weight loss in obese patients with higher dosing
• Helps decrease leptin and increase leptin sensitivity
• Can increase the conversion of white fat to brown fat
• 

 

 

 

our company 


 Hebei xianri biotechnology co.,ltd mainly focusing on dietary supplements processing in China, providing wide range of natural products with different forms including softgel, tablet, Capsules, vegetables hard capsules, powder and gummy. our R&D department providing value-added OEM and private label services for you.

Our company covers an area of 8 hectares and we have over 600 workers and staff members ,we owns five dietary supplement processing factories and two marine raw material extracting factories , which have passed the quality management certifications of GMP cGMP,HACCP,U.S.FDA,ISO9001,ISO14001,OHASAS18001 and BRC for global retails. We have imported 18 large soft gel production lines and more than 20 pieces of production equipment, such as fully automatic tablet compressing machines, hard capsule filling machines,3D mixers and coating machines, our daily production capacity of 20 million pieces of nutritional supplements and more than 1200 health products , bottling capability of 150 thousand bottles. We are largest production base of dietary supplements in Asia.

FAQ
How to contact us:
 
 
 
Address: No.392 Huaibei Road,Yuhua Districe, Shijiazhuang,China.
Our Payment Terms: 
Payment terms: 30% TT in advance as deposit for us to start the production, and the balance should be
TT after the shipment and before the seller release the Original B/L to buyer. 

Q: When can I get the price?
A: We usually quote within 24 hours after we get your inquiry.
If you are very urgent to get the price, please tell us so that we will regard your inquiry priority.
Q: How can I get a sample to check your quality?
A: After price confirmation, we are happy for sending samples in 2 days to you once you need.
Q: What about the lead time for mass production?
A: Honestly, it depends on the order quantity and the season you place the order. Always 1 month.
Q: What is your terms?
A: W accept EXW, FOB, CFR, CIF, DDU, DDP, etc. You can choose the one which is the most
convenient or cost effective for you.


To get more information, just feel free to contact with us. 
Sincerely looking forward to your cooperation.